Conexeu Sciences Inc. quarterly report, Q2 FY2026

Conexeu Sciences Inc. (CNXU) - 10-Q Summary

Business Context and Reporting Period

Company: Conexeu Sciences Inc.
Reporting Period: Quarter and six months ended April 30, 2026.
Business Model: Early-stage regenerative medicine company developing cellular therapies for skin restoration in wound care and aesthetics. The company has no commercial revenue and relies on capital raising to fund operations.
Status: Listed on Nasdaq (Symbol: CNXU) effective May 21, 2026 (Subsequent Event). Classified as an Emerging Growth Company and Smaller Reporting Company.

Key Financial Metrics

Metric Six Months Ended
April 30, 2026
Six Months Ended
April 30, 2025
Revenue $0 $0
Net Loss $(4,023,106) $(748,114)
Operating Expenses $4,103,327 $790,434
Cash & Cash Equivalents $6,848,064 $4,808,965 (Oct 31, 2025)
Restricted Cash $453,974 $25,155 (Oct 31, 2025)
Total Assets $8,199,679 $7,688,711 (Oct 31, 2025)
Accumulated Deficit $(8,544,626) $(4,521,520) (Oct 31, 2025)
Working Capital $6,910,389 N/A

Cash Flow (Six Months Ended April 30, 2026):
- Operating: $(3,340,281)
- Investing: $(34,831)
- Financing: $5,843,030 (Driven by private placements and warrant inducement program)

Material Changes vs. Prior Period

  • Expense Surge: Operating expenses increased by approximately 419% year-over-year (from $790k to $4.1M). This is primarily due to:
    • Consulting: Increased from $196k to $1.76M (regulatory and capital market advisors).
    • Management Salaries: Increased from $293k to $1.34M (expansion of executive team and stock-based compensation).
    • Professional Fees: Increased from $101k to $593k (legal/accounting costs for public listing).
  • Capital Raising: Significant financing activity occurred, including non-brokered private placements and a Regulation Crowdfunding offering, resulting in net proceeds of approximately $2.94M from private placements and $4.49M from Reg CF (closed in prior fiscal year but impacting current liquidity).
  • Stock-Based Compensation: Non-cash stock-based compensation increased to $494,453 for the six-month period (up from $91k in the prior year).

Outlook, Risks, and Management Commentary

  • Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern within one year without additional financing. Management estimates a cash runway of 9 to 11 months from April 30, 2026, based on a projected monthly burn rate of ~$700,000.
  • Strategic Milestones:
    • Nasdaq Listing: Achieved on May 21, 2026 (Subsequent Event).
    • Regulatory: Advancing toward a planned 510(k) submission to the FDA. Management anticipates submission by February 28, 2027.
    • Operations: Commenced a new laboratory lease on May 1, 2026.
  • Risks:
    • Dependence on a single device candidate (CXU™) with no commercial sales.
    • Need for additional equity or debt financing to fund operations and development.
    • Material weakness in internal controls over financial reporting regarding prepaid expenses (addressed with new procedures).
  • Subsequent Events:
    • Issued 4.3M shares and warrants under the Warrant Incentive Program (May 2026) for ~$1.97M proceeds.
    • Accelerated expensing of $137,377 in prepaid stock-based compensation due to early termination of a vendor agreement.
    • Board expansion from 6 to 9 members and appointment of a new Chief Commercial Officer (CCO).

Investor Verification Checklist

  • Cash Runway: Verify the accuracy of the 9-11 month cash runway estimate given the increased burn rate of $700k/month.
  • Related Party Transactions: Review Note 10 for significant compensation and consulting fees paid to directors and related entities (e.g., Director 7's company investing $2M+).
  • Stock-Based Compensation: Assess the impact of the $494k non-cash expense and future vesting obligations on future dilution.
  • Internal Controls: Confirm the effectiveness of the new procedures implemented to address the material weakness in prepaid expense accounting.
  • Regulatory Timeline: Monitor progress toward the anticipated February 2027 FDA 510(k) submission date.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.